Thus, the reactivation of microtubule functions through HDAC6 inhibition might reverse not only defects in microtubule-dependent transport, but also the accumulation of TDP-43 aggregates, providing a potential therapeutic approach for the TDP-43 proteinopathies, including ALS/FTD. Here, HDAC6 is linked to amyotrophic lateral sclerosis.